NutriBand (NTRB) Net Income towards Common Stockholders (2016 - 2026)
NutriBand (NTRB) posted Net Income towards Common Stockholders of -$1.2 million for Q2 2026, down 28.29% sequentially from -$968059.0 in Q1 2026, and up 10.58% YoY from -$1.1 million in Q2 2025.
NutriBand (NTRB) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
NutriBand has reported Net Income towards Common Stockholders for 11 years, with the latest figure at -$1.2 million in Q2 2026.
- Quarterly Net Income towards Common Stockholders rose 10.58% year-over-year to -$1.2 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$29.9 million (down 199.77% YoY) and the FY2026 annual result came in at -$30.0 million, down 186.61% from the prior year.
- Net Income towards Common Stockholders declined to -$1.2 million in Q2 2026 per NTRB's latest filing, from -$968059.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$689989.0 in Q2 2022 and troughed at -$23.8 million in Q3 2025.
- A 5-year average of -$3.1 million and a median of -$1.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders sank 1296.36% in 2025, then jumped 82.45% in 2026.
- Over 5 years, Net Income towards Common Stockholders stood at -$1.1 million in 2022, then sank by 63.64% to -$1.8 million in 2023, then climbed by 22.58% to -$1.4 million in 2024, then slumped by 184.18% to -$3.9 million in 2025, then jumped by 67.93% to -$1.2 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$1.2 million, -$968059.0, and -$3.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | NutriBand | 57.74 Mn | 53.73 Mn | 196,801.00 | -1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -1.24 Mn |
| Jan 31, 2026 | -968,059.00 |
| Oct 31, 2025 | -3.87 Mn |
| Jul 31, 2025 | -23.81 Mn |
| Apr 30, 2025 | -1.39 Mn |
| Jan 31, 2025 | -5.52 Mn |
| Oct 31, 2024 | -1.36 Mn |
| Jul 31, 2024 | -1.71 Mn |
| Apr 30, 2024 | -1.90 Mn |
| Jan 31, 2024 | -1.88 Mn |
| Oct 31, 2023 | -1.76 Mn |
| Jul 31, 2023 | -829,173.00 |
| Apr 30, 2023 | -1.02 Mn |
| Jan 31, 2023 | -1.68 Mn |
| Oct 31, 2022 | -1.08 Mn |
| Jul 31, 2022 | -1.04 Mn |
| Apr 30, 2022 | -689,989.00 |
| Jan 31, 2022 | -3.77 Mn |
| Oct 31, 2021 | -1.77 Mn |
| Jul 31, 2021 | -519,923.00 |